12 March 2019

Three critical questions life sciences CFOs need to answer on capital allocation

Life sciences companies have been able to access significant amounts of cash from overseas and increase their operating cash flow due to lower tax rates resulting from US tax reform. According to a recent EY survey, many life sciences companies have successfully reduced their working capital levels. This EY article provides details.

Document ID: 2019-5345